Gene-based vaccine approaches for respiratory syncytial virus

Current Topics in Microbiology and Immunology

Volumn 372, Issue , 2013, Pages 307-324

  Loomis, Rebecca J ^a   Johnson, Philip R ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHAVIRUS VECTOR; BACTERIAL VECTOR; DNA VACCINE; PARVOVIRUS VECTOR; POXVIRUS VECTOR; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; DNA IMMUNIZATION; DRUG DEVELOPMENT; GENE VECTOR; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLASMID; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ALPHAVIRUS; ANIMALS; CHILD, PRESCHOOL; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HOST SPECIFICITY; HUMANS; INFANT; MICE; POXVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, DNA;

EID: 84892764284     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38919-1_15     Document Type: Article

References (67)

1. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN (2010) New insights for development of a safe and protective RSV vaccine. Hum vaccines 6:482-492
2. Brave A, Ljungberg K, Wahren B, Liu MA (2007) Vaccine delivery methods using viral vectors. Mol Pharm 4:18-32. doi:10.1021/mp060098+
3. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG (1999) Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92:67-75. doi:10.1006/clim.1999.4724
4. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893. doi:10.1016/S0140-6736 (08) 61591-3
5. Cano F, Plotnicky-Gilquin H, Nguyen TN, Liljeqvist S, Samuelson P, Bonnefoy J, Stahl S, Robert A (2000) Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18:2743-2752
6. Chang J (2011) Current progress on development of respiratory syncytial virus vaccine. BMB reports 44:232-237. doi:DOI10.5483/BMBRep. 2011.44.4.232
7. Clark KR, Sferra TJ, Johnson PR (1997) Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 8:659-669. doi:10.1089/hum.1997.8.6-659
8. Collins PL, Melero JA (2011) Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:80-99. doi:10.1016/j.virusres.2011.09.020
9. Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR (1990) Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8:164-168
10. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR (1993) A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:1395-1404
11. De Waal L, Wyatt LS, Yuksel S, Van Amerongen G, Moss B, Niesters HG, Osterhaus AD, De Swart RL (2004) Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 22:923-926. doi:10.1016/j.vaccine.2003.10.010
12. Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, Egan MA, Boutilier LA, Melville K, Lerch RA, Long D, Eldridge JH, Parks CL, Udem SA, Hancock GE (2007) Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25:7132-7144. doi:10.1016/j.vaccine.2007.07.065
13. Falcone V, Mihm D, Neumann-Haefelin D, Costa C, Nguyen T, Pozzi G, Ricci S (2006) Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G. FEMS Immunol Med Microbiol 48:116-122. doi:10.1111/j.1574-695X. 2006.00130.x
14. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 53:296-302. doi:10.1093/cid/cir334
15. Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, Wang Y, Xie C, Tang Q, Wei W, Wang M, Song J, Qu J, Zhang Y, Hong T (2009) Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem Biophys Res Commun 381:528-532. doi:10.1016/j.bbrc.2009.02.075
16. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109:14604-14609. doi:10.1073/pnas.1209367109
17. Graham BS (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239:149-166. doi:10.1111/j.1600-065X.2010.00972.x
18. Graham FL (1990) Adenoviruses as expression vectors and recombinant vaccines. Trends Biotechnol 8:85-87
19. Greer CE, Zhou F, Legg HS, Tang Z, Perri S, Sloan BA, Megede JZ, Uematsu Y, Vajdy M, Polo JM (2007) A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25:481-489. doi:10.1016/j.vaccine.2006.07. 048
20. Hjorth RN, Bonde GM, Pierzchala WA, Vernon SK, Wiener FP, Levner MH, Lubeck MD, Hung PP (1988) A new hamster model for adenoviral vaccination. Arch Virol 100:279-283
21. Hsu KH, Lubeck MD, Bhat BM, Bhat RA, Kostek B, Selling BH, Mizutani S, Davis AR, Hung PP (1994) Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 12:607-612
22. Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, Mizutani S, Murphy BR, Collins PL, Chanock RM et al (1992) Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J Infect Dis 166:769-775
23. Hurwitz JL (2011) Respiratory syncytial virus vaccine development. Expert Rev Vaccines 10:1415-1433. doi:10.1586/erv. 11.120
24. Jiao S, Williams P, Berg RK, Hodgeman BA, Liu L, Repetto G, Wolff JA (1992) Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 3:21-33. doi:10.1089/hum.1992.3.1-21
25. Johnson DC, Ghosh-Choudhury G, Smiley JR, Fallis L, Graham FL (1988) Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector. Virology 164:1-14
26. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR (2005) Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79:955-965. doi:10.1128/JVI.79.2. 955-965.2005
27. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR (2009) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15:901-906. doi:10.1038/nm.1967
28. Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, Tenbusch M, Uberla K, Grunwald T (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 83:12601-12610. doi:10.1128/JVI.01036-09
29. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nature reviews. Genetics 9:776-788. doi:10.1038/nrg2432
30. Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M (2000) Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269:54-65. doi:10.1006/viro.2000.0186
31. Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M (1998) Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 188:681-688
32. Liniger M, Zuniga A, Naim HY (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6:255-266. doi:10.1586/14760584.6. 2.255
33. Mayr A, Stickl H, Muller HK, Danner K, Singer H (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin 167:375-390
34. McDermott MR, Graham FL, Hanke T, Johnson DC (1989) Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169:244-247
35. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR (2008) HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 372:1894-1905. doi:10.1016/S0140-6736 (08) 61592-5
36. Mehendale S, Van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE (2008) A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 24:873-880. doi:10.1089/aid.2008.0292
37. Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr (2007) Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 81:13710-13722. doi:10.1128/JVI.01351-07
38. Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:11341-11348
39. Murata Y (2009) Respiratory syncytial virus vaccine development. Clin Lab Med 29:725-739. doi:10.1016/j.cll.2009.07.004
40. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 83:7462-7466
41. Olszewska W, Suezer Y, Sutter G, Openshaw PJ (2004) Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23:215-221. doi:10.1016/j.vaccine.2004.05.015
42. Pacini DL, Dubovi EJ, Clyde WA Jr (1984) A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis 150:92-97
43. Palffy R, Gardlik R, Hodosy J, Behuliak M, Resko P, Radvansky J, Celec P (2006) Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 13:101-105. doi:10.1038/sj.gt.3302635
44. Panicali D, Davis SW, Weinberg RL, Paoletti E (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA 80:5364-5368
45. Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79:4927-4931
46. Paoletti E (1996) Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 93:11349-11353
47. Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285-1294. doi:10.1517/14712598.4.8.1285
48. Pemberton RM, Cannon MJ, Openshaw PJ, Ball LA, Wertz GW, Askonas BA (1987) Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J Gen Virol 68 (Pt 8):2177-2182
49. Piccini A, Paoletti E (1986) The use of vaccinia virus for the construction of recombinant vaccines. BioEssays: News Rev Mole Cell Dev Biol 5:248-252. doi:10.1002/bies.950050604
50. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401. doi:10.1006/viro.1997.8878
51. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ (2002) Crosspackaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791-801
52. Samulski RJ, Berns KI, Tan M, Muzyczka N (1982) Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 79:2077-2081
53. Schickli JH, Dubovsky F, Tang RS (2009) Challenges in developing a pediatric RSV vaccine. Hum Vaccines 5:582-591
54. Schlesinger S, Dubensky TW (1999) Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 10:434-439
55. Small JC, Ertl HC (2011) Viruses-from pathogens to vaccine carriers. Curr Opin Virol 1:241-245. doi:10.1016/j.coviro.2011.07.009
56. Smerdou C, Liljestrom P (1999) Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther 1:244-251
57. Smith GL, Moss B (1983) Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25:21-28
58. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD (2008) Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol CVI 15:460-467. doi:10.1128/CVI.00431-07
59. Ternette N, Tippler B, Uberla K, Grunwald T (2007) Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25:7271-7279. doi:10.1016/j.vaccine.2007.07.025
60. Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt C (2010) A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses 26:933-942. doi:10.1089/aid.2009.0242
61. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468
62. Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mole Ther J Am Soc Gene Ther 14:316-327. doi:10.1016/j.ymthe.2006.05.009
63. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B (1999) Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18:392-397
64. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC (2003) Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77:10780-10789
65. Xie C, He JS, Zhang M, Xue SL, Wu Q, Ding XD, Song W, Yuan Y, Li DL, Zheng XX, Lu YY, Shang Z (2007) Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther 18:746-752. doi:10.1089/hum.2007.053
66. Xin KQ, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K, Nomiyama H, Saito T, Imai M, Monahan J, Okuda K, Ozawa K (2001) A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 12:1047-1061. doi:10.1089/ 104303401750214276
67. Yu JR, Kim S, Lee JB, Chang J (2008) Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 82:2350-2357. doi:10.1128/JVI.02372-07